These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11953478)

  • 41. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral therapy in the experienced patient.
    Gallant JE
    Hopkins HIV Rep; 1999 Mar; 11(2):1, 4, 9, 16. PubMed ID: 11366245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
    Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
    J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
    [No Abstract]   [Full Text] [Related]  

  • 44. New drugs on the horizon.
    Proj Inf Perspect; 1998 Apr; (24):10-3. PubMed ID: 11365712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
    Parienti JJ
    AIDS; 2002 Oct; 16(15):2097; author reply 2098. PubMed ID: 12370515
    [No Abstract]   [Full Text] [Related]  

  • 46. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretroviral therapy for previously treated patients.
    Montaner JS; Mellors JW
    N Engl J Med; 2001 Aug; 345(6):452-5. PubMed ID: 11496858
    [No Abstract]   [Full Text] [Related]  

  • 48. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 49. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H;
    AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 52. Novel approaches for the treatment of HIV.
    Arroyo HT
    Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Don't mix Sustiva with Fortovase.
    Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drugs of tomorrow.
    Posit Aware; 1998; 9(3):27-31. PubMed ID: 11365484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
    TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
    [No Abstract]   [Full Text] [Related]  

  • 58. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Mata R; Gómez-Vera J; Alarcón A; Pachón J
    J Acquir Immune Defic Syndr; 2003 Feb; 32(2):240-2. PubMed ID: 12571537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.